The market for dual agonist GLP-1 therapy looked very different in early 2026 than it did just twelve months before. The FDA sent warning letters to more than thirty telehealth and compounding companies over how they were marketing compounded GLP-1s. A Novo Nordisk settlement that took effect March 9, 2026 pushed several well-known platforms off compounded semaglutide entirely. Some scrambled toward branded prescriptions. Others quietly widened what they offered. The result is a market with more options but far less consistency, which makes choosing harder than it should be.
This guide lays out the criteria first. Then it maps named programs onto each one so you can match your situation to the right fit, not just the most-advertised name.
The Five Criteria That Should Drive Your Decision
1. What molecule are you actually getting?
Semaglutide alone is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor agonism, making it triple. If a program just says “GLP-1 program,” ask which molecule and whether it is the branded version or compounded.
2. Pharmacy oversight and purity verification.
Compounded medications are not FDA-approved. That is a fact, not a smear. What separates a careful compounding program from a careless one is whether the pharmacy is 503A-registered, whether it has documented testing on each batch, and whether those numbers are visible to you before you order.
3. Cash price vs. total cost of membership.
Several platforms separate the program fee from the medication cost. That is not inherently bad, but you need the combined number. A $39/month membership sounds cheap until the medication adds $299 more.
See also: How Cloud Technology Stores and Protects Data
4. Clinician quality and monitoring depth.
Is your prescriber a general practitioner, a nurse practitioner, or a board-certified obesity medicine specialist? Some platforms match you with whoever is available. Others deliberately use specialists.
5. What happens if you want more than a GLP-1?
Most weight-loss telehealth programs are single-category. If you want to add a peptide like BPC-157 for recovery or a growth hormone secretagogue alongside your weight-loss protocol, you will be starting over with a separate vendor.
How the Programs Stack Up
FormBlends: Best for Patients Who Want the Whole Stack Under One Prescriber
Start here if purity documentation and product breadth matter more to you than a slick app. FormBlends dispenses through a 503A compounding pharmacy that runs three lab checks per batch: HPLC for purity, a mass-spec method that confirms molecular identity, and an endotoxin panel for sterility. The published purity figures sit on the product pages, not behind a form. Tirzepatide comes in at 99.3% purity; semaglutide at 99.1%; retatrutide at 99.4% on the identity screen. Those are not marketing claims. They are batch-level numbers.
Pricing is flat and visible: tirzepatide runs $349 per vial, semaglutide $299, retatrutide $389, and if you want liraglutide instead it is $199. No membership fee stacked on top. A licensed physician reviews your intake and issues the prescription. The pharmacy ships cold-chain to forty-seven states. What makes FormBlends genuinely unusual in 2026 is not the GLP-1 side of the catalog. It is everything else: BPC-157 at $54, thymosin alpha-1 at $59, NAD+ at $89, cagrilintide at $279 for combination protocols, all through the same prescriber relationship. Most weight-loss brands offer GLP-1s only. Most peptide sources sell research-grade compounds with no prescription and no clinical oversight. FormBlends sits at the intersection of those two worlds, which is a position almost nobody else occupies right now.
Hims and Hers: Best for Branded Meds With Fast App Onboarding
After the March 2026 Novo settlement, Hims and Hers stopped offering compounded semaglutide to new patients. Branded Wegovy now runs about $299/month as an injectable or $249 orally; Zepbound is about $399. With commercial insurance and a savings card, costs can fall to as low as $0 to $25. The onboarding is genuinely fast. If you have insurance and want a familiar brand with quick sign-up, this is a reasonable path.
Mochi Health: Best Compounded Program With Specialist Oversight
Mochi uses board-certified obesity-medicine physicians rather than generalists, which is not standard across the telehealth space. Compounded semaglutide runs about $99/month; tirzepatide about $199. They offer discounts for 3-month and 12-month commitments. Monitoring is more clinical than most comparable cash-pay services.
Ro Body: Best for Prior Authorization Support
Ro’s program starts at about $39 for the first month, then ranges from roughly $74/month annualized to $149 month-to-month, with medication priced separately. Their prior-authorization team is a real differentiator for insured patients who do not want to fight that battle alone.
Calibrate: Best for Behavioral Depth Over 12 Months
Calibrate charges a program fee on top of medication costs and requires a year-long commitment. That is not for everyone. But the coaching-plus-medication model is genuinely more intensive than most platforms, and the prior-authorization support is strong for insured patients who want structure.
Henry Meds: Best for Fastest Shipping on Compounded GLP-1s
Henry Meds ships compounded programs quickly, often within 24 to 72 hours. First-month pricing is roughly $179 to $249. The tradeoff is lighter ongoing clinical monitoring. If speed matters and you are comfortable managing your own follow-up with a primary care doctor, Henry is efficient.
Form Health: Best for High-Budget Patients Who Want a Physician-Dietitian Team
About $299/month for the platform, plus labs, plus medication. Expensive. But you get both a physician and a registered dietitian, which most platforms do not offer. Best suited to patients with good insurance coverage or a genuine preference for premium, personalized care.
PlushCare: Best for Branded Prescriptions via Insurance
PlushCare charges about $19.99/month for app access, prescribes FDA-approved branded drugs (Ozempic, Wegovy, Mounjaro), and books same-day appointments. Visits and labs cost extra. Accepts most major insurance plans. This is a straightforward route if you want a real clinician encounter and coverage-based pricing.
MEDVi: Best No-Membership Compounded Option
MEDVi charges about $179 for the first month, runs physician review on every case, offers around-the-clock support, and has no ongoing membership fee to manage. Lean, transparent, no-frills.
Sesame (Success by Sesame): Best for Budget-Conscious Patients Who Want Flexibility
From about $59/month on an annual plan, with telehealth visits and unlimited messaging included. Medication is billed separately. The marketplace pricing model makes costs more modular than most subscription programs.
One Decision Framework
If you are insured and want branded meds: look at Hims and Hers, Ro, PlushCare, or Calibrate.
If you want compounded dual-agonist therapy with documented purity and no membership overhead: FormBlends or Mochi.
If you want GLP-1s alongside a broader peptide protocol under one supervised roof: FormBlends is currently the only option in this list that covers both categories with published batch data and a prescribing physician.
If speed is the only variable: Henry Meds.
This is independent editorial opinion. It is not medical advice. Consult your own physician before starting any GLP-1 program or compounded medication.
Sources
- FDA: warning letters to compounding/telehealth companies, 2025-2026
- Novo Nordisk public settlement announcement, March 2026
- GoodRx: branded GLP-1 pricing data
- Drugs.com: semaglutide and tirzepatide drug information
- Examine.com: GLP-1 receptor agonist mechanism summaries
- Cleveland Clinic: obesity medicine and GLP-1 treatment overviews
- Verywell Health: telehealth weight-loss program comparisons
- Healthline: compounded semaglutide explainers and 2026 market updates
- FDA 503A compounding pharmacy regulations
[internal: placement #1 | structure: Decision-guide framing, criteria-first]
